ID   Hs 895.T
AC   CVCL_0993
SY   Hs-895-T; Hs 895 T; Hs895.T; Hs895T; HS895T
DR   CLO; CLO_0004200
DR   EFO; EFO_0006593
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-7637
DR   BCRJ; 0336
DR   BioSample; SAMN03472962
DR   BioSample; SAMN10987618
DR   cancercelllines; CVCL_0993
DR   Cell_Model_Passport; SIDM01743
DR   DepMap; ACH-000043
DR   EGA; EGAS00001000610
DR   GEO; GSM827552
DR   GEO; GSM887127
DR   GEO; GSM888198
DR   IARC_TP53; 30072
DR   LiGeA; CCLE_078
DR   PharmacoDB; Hs895_T_607_2019
DR   PRIDE; PXD007265
DR   Progenetix; CVCL_0993
DR   Wikidata; Q54896180
RX   DOI=10.1101/166199;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=29275043;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Problematic cell line: Misclassified. Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: 35.2 +- 1.45 hours (PubMed=29275043).
CC   HLA typing: A*01:01,25:01; B*07:02,08:01; C*07:02,07:02; DQA1*01:02,03:02; DQB1*02:02,02:02; DRB1*04:05,11:09 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Secretome proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.77%; Native American=1.02%; East Asian, North=0.49%; East Asian, South=0%; South Asian=0.06%; European, North=67.7%; European, South=29.96% (PubMed=30894373).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
ST   Source(s): ATCC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 12,14
ST   D18S51: 12,15
ST   D21S11: 30,31
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 13,15
ST   FGA: 19,25
ST   Penta D: 11,12
ST   Penta E: 7,17
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0992 ! Hs 895.Sk
SX   Female
AG   48Y
CA   Undefined cell line type
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1101/166199;
RA   de Weck A., Bitter H., Kauffmann A.;
RT   "Fibroblasts cell lines misclassified as cancer cell lines.";
RL   bioRxiv 2017:166199-166199(2017).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29275043; DOI=10.1016/j.jprot.2017.12.013;
RA   Liberato T., Pessotti D.S., Fukushima I., Kitano E.S., Serrano S.M.T.,
RA   Zelanis A.;
RT   "Signatures of protein expression revealed by secretome analyses of
RT   cancer associated fibroblasts and melanoma cell lines.";
RL   J. Proteomics 174:1-8(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//